Application of gibberelic acid (GA) alone or together wih cytostatics in treatment of lung cancer.
Gibberelic acid (GA) was used alone or in combination with cytostatics (Vincristine, Cyclophosphamide, HN3), surgical treatment or radiotherapy, in treatment of 65 patients with lung cancer. The patinets were followed up from the end of 1972 until the end of 1977. It was found that the administration of GA, at the given doses, did not cause toxic effects in treated patients and it improved for shorter or longer period of time some metabolic functions and activity of hemopoiesis. Some analgetic effect(2) of GA was also registered.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005875:Gibberellins / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D005875:Gibberellins; D014750:Vincristine; D003520:Cyclophosphamide